Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROSHAN KOTHA

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1417117839
CMS profile
154450
Location
LA MESA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$30,664.06

185 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROSHAN KOTHA

NPI 1417117839 · CMS profile ID 154450

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

LA MESA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417117839?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROSHAN KOTHA, NPI 1417117839, CMS profile ID 154450. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417117839?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROSHAN KOTHA, NPI 1417117839, CMS profile ID 154450. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417117839?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROSHAN KOTHA, NPI 1417117839, CMS profile ID 154450, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417117839?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

185 matching records · $30,664.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 185 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–185 of 185.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $5.5104/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672031644 CMS
Janssen Biotech, Inc. $17.4103/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658535459 CMS
Novartis Pharmaceuticals Corporation $23.3103/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659692773 CMS
PFIZER INC. $17.6203/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672012441 CMS
GlaxoSmithKline, LLC. $16.2203/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670340379 CMS
AbbVie, Inc. $1,500.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741889 CMS
AbbVie, Inc. $14.9903/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741783 CMS
Mallinckrodt Enterprises LLC $13.1103/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704775959 CMS
AbbVie, Inc. $7.2903/12/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741887 CMS
AbbVie, Inc. $16.5203/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741891 CMS
AbbVie, Inc. $335.6503/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741893 CMS
AbbVie, Inc. $9.7103/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741771 CMS
Celgene Corporation $3.0903/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672778963 CMS
Janssen Biotech, Inc. $560.0003/06/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658535443 CMS
Janssen Biotech, Inc. $50.0003/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658535451 CMS
Novartis Pharmaceuticals Corporation $21.3403/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659692771 CMS
Janssen Biotech, Inc. $4.2203/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658535441 CMS
PFIZER INC. $6.7903/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672110911 CMS
PFIZER INC. $14.4302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672040631 CMS
Mallinckrodt Enterprises LLC $26.4602/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704775957 CMS
Amgen Inc. $24.9202/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662974789 CMS
Novartis Pharmaceuticals Corporation $19.4802/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659692769 CMS
Celgene Corporation $14.2902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673001759 CMS
Celgene Corporation $8.9002/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672746115 CMS
Novartis Pharmaceuticals Corporation $19.3802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659692781 CMS
Lilly USA, LLC $16.8102/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658121517 CMS
PFIZER INC. $18.5201/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672009081 CMS
AbbVie, Inc. $15.6201/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741883 CMS
AbbVie, Inc. $1,500.0001/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741881 CMS
AbbVie, Inc. $7.2901/23/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741877 CMS
AbbVie, Inc. $16.7701/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741879 CMS
AbbVie, Inc. $359.6301/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741885 CMS
PFIZER INC. $15.3501/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672093033 CMS
Lilly USA, LLC $15.1701/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658124827 CMS
Amgen Inc. $26.8501/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662974787 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30,664.06 185
PY2020 $15,779.16 101
PY2021 $10,220.34 122
PY2022 $39,226.27 181
PY2023 $40,054.07 162
PY2024 $59,365.13 214
PY2025 $47,096.97 310

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $170,991.84 27
PY2024 Recipient $1,911.66 2
PY2024 Principal investigator $142,751.89 34
PY2023 Recipient $2,236.60 2
PY2023 Principal investigator $418,533.32 55
PY2022 Principal investigator $710,751.61 46
PY2021 Principal investigator $424,806.37 35
PY2020 Principal investigator $166,997.47 52
PY2019 Principal investigator $240,389.30 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,856.48 12/17/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA M
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289782
Principal investigator 1 ABBVIE INC. $2,371.50 12/04/2025 Non-covered Recipient Entity
ROSHAN KOTHA PURUSHOTHAN &
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527964
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,031.08 11/21/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA M
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288653
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,375.00 11/05/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA M
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288071
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,800.00 11/05/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA M
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288073
Principal investigator 1 ABBVIE INC. $1,480.00 11/04/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202520623
Principal investigator 1 ABBVIE INC. $1,790.40 11/04/2025 Non-covered Recipient Entity
ROSHAN KOTHA PURUSHOTHAN &
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520625
Principal investigator 1 ABBVIE INC. $1,218.40 10/30/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202519851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,002.48 10/15/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA M
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,758.20 09/24/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA MD INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285842
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,765.10 09/03/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA MD INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284923
Principal investigator 1 ABBVIE INC. $1,218.40 08/05/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202501722
Principal investigator 1 ABBVIE INC. $1,218.40 07/02/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202494241
Principal investigator 1 Eli Lilly and Company $8,039.00 07/01/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHER, MD, INC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187888334
Principal investigator 1 Aurinia Pharma U.S., Inc. $7,500.00 06/18/2025 Non-covered Recipient Entity
Purushotham & Akther Kotha MD, Inc.
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930820
Principal investigator 1 ABBVIE INC. $1,871.00 06/03/2025 Non-covered Recipient Entity
ROSHAN KOTHA PURUSHOTHAN &
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202489475
Principal investigator 1 ABBVIE INC. $1,218.40 05/06/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202482283
Principal investigator 1 ABBVIE INC. $2,871.00 05/06/2025 Non-covered Recipient Entity
ROSHAN KOTHA PURUSHOTHAN &
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202482285
Principal investigator 1 Eli Lilly and Company $49,220.00 04/22/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHER, MD, INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187888210
Principal investigator 1 ABBVIE INC. $1,218.40 04/03/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202471161
Principal investigator 1 ABBVIE INC. $8,162.30 04/03/2025 Non-covered Recipient Entity
ROSHAN KOTHA PURUSHOTHAN &
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471165
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,282.80 03/12/2025 Non-covered Recipient Entity
Purushotham & Akther Kotha MD, Inc.
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930950
Principal investigator 1 ABBVIE INC. $1,218.40 03/06/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202456866
Principal investigator 1 ABBVIE INC. $1,871.00 03/06/2025 Non-covered Recipient Entity
ROSHAN KOTHA PURUSHOTHAN &
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202456944
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 02/26/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHA MD INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223275689
Principal investigator 1 Eli Lilly and Company $674.10 02/25/2025 Non-covered Recipient Entity
PURUSHOTHAM AND AKTHER KOTHER, MD, INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187888324
Principal investigator 1 ABBVIE INC. $2,960.00 01/02/2025 Non-covered Recipient Entity
PURUSHOTHAM & AKTHER KOTHA MD
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202436174